Smoking Cessation Invention in the Emergency Department (ED)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01173653|
Recruitment Status : Completed
First Posted : August 2, 2010
Results First Posted : November 19, 2012
Last Update Posted : December 27, 2012
The emergency department (ED) serves a vital and growing role in the US health care system, responsible for both the delivery of emergent medical care and for safety-net care for populations without traditional access to health services. Uninsured populations rely significantly on the safety-net services of the ED. Between 2000-2005 the number of uninsured Americans increased from 39.6 million to 46.1 million, and this growth is expected to continue. Many health policy analysts consider the ED to be an effective place to provide preventative care. Prophylactic tetanus immunization, for example, has been a successful preventive health intervention that has become a standard of care in the ED setting. Brief smoking cessation interventions have been introduced in the ED but have not had great success based on lack of follow-up and continuity.
Our study is novel in that it introduces a brief smoking intervention through use of an established, federally-funded and federally-sponsored cessation counseling resource, the National Smoking Cessation Quit Line, also available at smokefree.gov. This is a joint initiative between the Tobacco Control Research Branch of the National Cancer Institute and the Centers for Disease Control and Prevention. Since ED patients who smoke often lack the ability to use self-help cessation resources, we hypothesize that by introducing this population to the counselors on the National Smoking Cessation Quit Line (also called the 1-800-QUIT-NOW line) during the ED visit via phone, that this new brief intervention would have a realizable and significant effect on smoking cessation among the this population.
|Condition or disease||Intervention/treatment|
|Smoking Cessation Tobacco Use Cessation Health Behavior||Other: Smoking Cessation|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||199 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Trial of Directed Smoking Cessation Intervention in the Emergency Care Population|
|Study Start Date :||July 2010|
|Primary Completion Date :||October 2010|
|Study Completion Date :||January 2011|
Placebo Comparator: Standard EM Smoking Cessation Info
Patients discharged from ER receive pamphlet re: smoking cessation
Other: Smoking Cessation
Randomly introducing patients to a Department of Health program to help them quit smoking.
Active Comparator: Patients contact 1-800-QUIT-NOW before leaving ED
Prior the patient leaving the ED, the PI will assist the patient with contacting 1-800-QUIT-NOW, who will help patient to quit smoking.
Other: Smoking Cessation
A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
- Smoking Status at Follow up [ Time Frame: 6 weeks ]Patients enrolled in this study were contacted via phone to assess smoking status. Smoking status was a self-report from each subject. Primary outcome measure is the smoking status of the enrollee at the time of follow-up contact. We calculated the percentage of participants who had stopped smoking at the 6 week follow-up period in each arm
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01173653
|United States, Tennessee|
|Vanderbilt University Medical Center - Emergency Medicine|
|Nashville, Tennessee, United States, 37232-4700|
|Principal Investigator:||Ben Heavrin, MD||Vanderbilt University Medical Center|